FDA staff questions value of Vertex's cystic fibrosis combo

(Reuters) - Staff reviewers from the U.S. FDA questioned whether Vertex Pharmaceuticals Inc's experimental combination therapy for cystic fibrosis had an added benefit over the company's already approved therapy, Kalydeco, in patients with the most common genetic mutation behind the deadly disease.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news